What is the main business of Sanzyme Europe?

The main business activity of Sanzyme Europe focuses on manufacture of pharmaceutical preparations.

When was the company founded?

The company was registered in the Polish National Court Register (KRS) on April 15, 2016.

Where is the headquarters located?

The headquarters is located at: ul. Prosta 67, 00-838 Warszawa.

What is the share capital?

The share capital of the company is PLN 270,000 (approx. $72,934).

What period do the latest financial data cover?

The latest available financial statement covers the period from April 1, 2024 to March 31, 2025.

What was the revenue?

The company reported a revenue of USD 0 in 2025, which is a decrease of 9.0% compared to 2024.

Is the company profitable?

No, in 2025 the company was not profitable, reporting a net loss of USD 6,329. For comparison, in 2024 the loss was USD 4,894, meaning the company increased its loss by 29.0%.

Sanzyme Europesp. z o.o.

Manufacture of pharmaceutical preparations

KRS: NIP: REGON:

Overview

Status

Active

Registry date

2016-04-15

Share capital

270,000.00 PLN

Registered address

ul. Prosta 67, 00-838 Warszawa, Poland

Electronic delivery address

AE:PL-34684-17533-TAIJF-20

Financials

Revenue history

Filing timeliness

1 of 6 financial statements was filed late (for 2023, 178 days late).

202615/10/2026
202515/10/2025
202420/08/2024
202310/04/2024
202214/07/2022
202113/10/2021

Filed on timeDelayFiling deadline

Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.

Statistics

How the company ranks by revenue within its industry, region and across Poland in 2026.

Results vs industry

Revenue

This companyUSD 325.63MedianUSD 917.74kAverageUSD 25.73m

Net profit

This companyUSD -3.40kMedianUSD 14.44kAverageUSD 2.75m

Operating costs

This companyUSD 3.73kMedianUSD 860.03kAverageUSD 21.34m

Assets

This companyUSD 19.62kMedianUSD 883.09kAverageUSD 31.39m

Industry

Trademarks

Sanzyme Europe holds 5 active trademarks registered with the Polish Patent Office. 2 marks have expired or were not registered. The first mark was filed in 2022.

Mark	Number	Classes	Status	Protected until
PUBERGEN(word)	Z.563568	5	Protected	Dec 8, 2033
SUGEST(word)	Z.563567	5	Protected	Dec 8, 2033
GYNOGEN(word)	Z.563569	5	Protected	Dec 8, 2033
SPORLAC(word)	Z.545988	1, 5	Protected	Aug 9, 2032
LOBUN(word)	Z.545986	5	Protected	Aug 9, 2032

Mark	Protected until
PUBERGEN(word)	Dec 8, 2033
SUGEST(word)	Dec 8, 2033
GYNOGEN(word)	Dec 8, 2033
SPORLAC(word)	Aug 9, 2032
LOBUN(word)	Aug 9, 2032

Authorized Representatives

Jay Laxman Soman – President of the Management Board

Venkata Subrahmanyaprasad Kompella – Management Board Member

Manner of representation

Each member of the management board is authorized to make declarations on behalf of the company independently.

Ownership

Owner	Shares	Share value	Stake
Sanzyme Private Limited	2,700	$72,933.55	100%

Beneficial owners

Person	Rights

Bank accounts

Registered as a VAT taxpayer on 2016-05-01.

No bank accounts reported to the VAT Taxpayer Register.

Debt

No entries in the National Debtors Register (KRZ).

Public aid

No public aid cases recorded in the last 10 years.

Competitors

Name	Revenue	Website
Auxilius PharmaS.A.	$0.83	auxiliuspharma.com
Bliss Pharmasp. z o.o.	$0.69	bliss-pharma.com
Healthtech Pharmsp. z o.o.	$0.07	healthtechpharm.com

Change history

Date	Event
2025-02-20	Address change (Ul. Grzybowska 5a, 00-132, Warszawa → Ul. Prosta 67, 00-838, Warszawa)
2025-02-20	Share capital increase (200,000.00 PLN → 270,000.00 PLN)
2020-10-15	Share capital increase (100,000.00 PLN → 200,000.00 PLN)
2018-12-19	Address change (Ul. Koszykowa 54, 00-675, Warszawa → Ul. Grzybowska 5a, 00-132, Warszawa)
2018-07-03	Share capital increase (25,000.00 PLN → 100,000.00 PLN)

FAQ

Last updated: 2026-10-15